Show simple item record

dc.contributor.authorHutchings, M.
dc.contributor.authorRadford, John A
dc.contributor.authorAnsell, S. M.
dc.contributor.authorIllés, Á.
dc.contributor.authorSureda, A.
dc.contributor.authorConnors, J. M.
dc.contributor.authorSýkorová, A.
dc.contributor.authorShibayama, H.
dc.contributor.authorAbramson, J. S.
dc.contributor.authorChua, N. S.
dc.contributor.authorFriedberg, J. W.
dc.contributor.authorKořen, J.
dc.contributor.authorLaCasce, A. S.
dc.contributor.authorMolina, L.
dc.contributor.authorEngley, G.
dc.contributor.authorFenton, K.
dc.contributor.authorJolin, H.
dc.contributor.authorLiu, R.
dc.contributor.authorGautam, A.
dc.contributor.authorGallamini, A.
dc.date.accessioned2021-03-08T06:18:46Z
dc.date.available2021-03-08T06:18:46Z
dc.date.issued2021en
dc.identifier.citationHutchings M, Radford J, Ansell SM, Illes A, Sureda A, Connors JM, et al. Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. Hematol Oncol. 2021.en
dc.identifier.pmid33462822en
dc.identifier.doi10.1002/hon.2838en
dc.identifier.urihttp://hdl.handle.net/10541/623783
dc.description.abstractApproximately one-third of patients diagnosed with Hodgkin lymphoma presenting with Stage IV disease do not survive past 5 years. We present updated efficacy and safety analyses in high-risk patient subgroups, defined by Stage IV disease or International Prognostic Score (IPS) of 4-7, enrolled in the ECHELON-1 study that compared brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as first-line therapy after a median follow-up of 37.1 months. Among patients treated with A + AVD (n = 664) or ABVD (n = 670), 64% had Stage IV disease and 26% had an IPS of 4-7. Patients with Stage IV disease treated with A + AVD showed consistent improvements in PFS at 3 years as assessed by investigator (hazard ratio [HR], 0.723; 95% confidence interval [CI], 0.537-0.973; p = 0.032). Similar improvements were seen in the subgroup of patients with IPS of 4-7 (HR, 0.588; 95% CI, 0.386-0.894; p = 0.012). The most common adverse events (AEs) in A + AVD-treated versus ABVD-treated patients with Stage IV disease were peripheral neuropathy (67% vs. 40%) and neutropenia (71% vs. 55%); in patients with IPS of 4-7, the most common AEs were peripheral neuropathy (69% vs. 45%), neutropenia (66% vs. 55%), and febrile neutropenia (23% vs. 9%), respectively. Patients in high-risk subgroups did not experience greater AE incidence or severity than patients in the total population. This updated analysis of ECHELON-1 shows a favorable benefit-risk balance in high-risk patients.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1002/hon.2838en
dc.titleBrentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 studyen
dc.typeArticleen
dc.contributor.departmentDepartment of Haematology and Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark.en
dc.identifier.journalHematological Oncologyen
dc.description.noteen]
refterms.dateFOA2021-03-08T13:35:30Z


Files in this item

Thumbnail
Name:
33462822.pdf
Size:
482.8Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record